Clinical Trial Update: Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing secukinumab in Japanese patients with generalized pustular psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-03-15